- Report
- September 2022
- 127 Pages
North America
From €2027EUR$2,100USD£1,739GBP
€2896EUR$3,000USD£2,484GBP
- Report
- June 2022
- 277 Pages
Global
From €3074EUR$3,185USD£2,637GBP
€4392EUR$4,550USD£3,767GBP
- Report
- January 2022
- 90 Pages
North America
From €4585EUR$4,750USD£3,933GBP
- Report
- October 2023
- 90 Pages
India
From €3378EUR$3,500USD£2,898GBP
- Report
- January 2023
- 132 Pages
Global
From €4295EUR$4,450USD£3,684GBP
- Report
- June 2021
- 32 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Clinical Trials
- September 2018
- 700 Pages
Global
From €2896EUR$3,000USD£2,484GBP
- Report
- May 2023
- 96 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- February 2024
- 168 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- June 2022
- 250 Pages
Global
From €5568EUR$5,769USD£4,776GBP
The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer.
The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries.
Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more
